(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 March 2012 (15.03.2012)

PCT

(10) International Publication Number
WO 2012/032764 A1

(51) **International Patent Classification**:
C12N 15/09 (2006.01) ***A61P 35/00*** (2006.01)
A61K 38/00 (2006.01) ***C07K 7/06*** (2006.01)
A61K 39/00 (2006.01) *C12N 9/10* (2006.01)

(21) **International Application Number**:
PCT/JP2011/004987

(22) **International Filing Date**:
6 September 2011 (06.09.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/380,611 7 September 2010 (07.09.2010) US

(71) **Applicant** *(for all designated States except US)*: **ONCOTHERAPY SCIENCE, INC.** [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **NAKAMURA, Yusuke** [JP/JP]; c/o The Institute of Medical Science, THE UNIVERSITY OF TOKYO, 6-1, Shirokanedai 4-chome, Minato-ku, Tokyo, 1088639 (JP). **TSUNODA, Takuya** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP). **OSAWA, Ryuji** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP).

(74) **Agents**: **SHIMIZU, Hatsushi** et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/032764 A1

(54) Title: TTLL4 PEPTIDES AND VACCINES CONTAINING THE SAME

(57) Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from TTLL4 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTLL4, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.